Lenox Wealth Management Inc. Purchases 479 Shares of Icon Plc (NASDAQ:ICLR)

Lenox Wealth Management Inc. increased its stake in shares of Icon Plc (NASDAQ:ICLR) by 5.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,309 shares of the medical research company’s stock after acquiring an additional 479 shares during the period. Lenox Wealth Management Inc.’s holdings in Icon were worth $1,371,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quest Capital Management Inc. ADV bought a new stake in Icon during the third quarter worth about $35,000. SRS Capital Advisors Inc. bought a new stake in Icon during the second quarter worth about $47,000. UBS Asset Management Americas Inc. raised its holdings in Icon by 30.9% during the second quarter. UBS Asset Management Americas Inc. now owns 326 shares of the medical research company’s stock worth $50,000 after acquiring an additional 77 shares in the last quarter. FTB Advisors Inc. raised its holdings in Icon by 27.6% during the third quarter. FTB Advisors Inc. now owns 361 shares of the medical research company’s stock worth $52,000 after acquiring an additional 78 shares in the last quarter. Finally, CWM LLC raised its holdings in Icon by 65.0% during the third quarter. CWM LLC now owns 386 shares of the medical research company’s stock worth $57,000 after acquiring an additional 152 shares in the last quarter. Institutional investors and hedge funds own 83.96% of the company’s stock.

Several analysts recently issued reports on ICLR shares. BidaskClub lowered Icon from a “buy” rating to a “hold” rating in a report on Monday, September 30th. UBS Group set a $160.00 target price on Icon and gave the stock a “hold” rating in a report on Friday, October 25th. Mizuho upped their price objective on Icon from $160.00 to $170.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Zacks Investment Research upgraded Icon from a “sell” rating to a “hold” rating in a research note on Wednesday, October 23rd. Finally, Credit Suisse Group restated a “buy” rating and issued a $160.00 price objective on shares of Icon in a research note on Monday, October 28th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $163.25.

NASDAQ:ICLR traded up $0.63 on Friday, hitting $145.91. The company’s stock had a trading volume of 183,700 shares, compared to its average volume of 265,994. Icon Plc has a one year low of $118.10 and a one year high of $165.13. The firm has a market capitalization of $8.07 billion, a P/E ratio of 23.20, a price-to-earnings-growth ratio of 2.02 and a beta of 0.69. The company has a current ratio of 2.07, a quick ratio of 2.07 and a debt-to-equity ratio of 0.28. The stock has a fifty day moving average of $146.90 and a two-hundred day moving average of $147.91.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $1.74 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.74. The business had revenue of $710.40 million during the quarter, compared to analyst estimates of $709.75 million. Icon had a return on equity of 25.30% and a net margin of 13.16%. Icon’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $1.54 EPS. As a group, sell-side analysts anticipate that Icon Plc will post 6.89 EPS for the current year.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: How can investors find ex-dividend dates?

Institutional Ownership by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.